Value of cardiac biomarkers in patients with acute pulmonary embolism

Arram, Eman O.; Fathy, Amal; Abdelsamad, Ayman A.; Elmasry, Emad I.

doi:10.1016/j.ejcdt.2013.09.016

Egyptian Journal of Chest Diseases and Tuberculosis

2014

DOI: 10.1016/j.ejcdt.2013.09.016

|View full text |Cite

Value of cardiac biomarkers in patients with acute pulmonary embolism

Eman O. Arram

Amal Fathy

Ayman A. Abdelsamad

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study re-confirms findings of our previous finding that patients with RV dysfunction (RV/LV ratio >1.2) were more likely to have greater clot burden, and septal bowing (34). Arram et al (35) suggested that troponin and myoglobin testing can be integrated with risk assessment of acute PE to guide treatment. The authors concluded that PE patients with normal troponin and myoglobin values could be successfully managed with anticoagulation therapy alone.…”

mentioning

confidence: 99%

Implications of elevated cardiac troponin in patients presenting with acute pulmonary embolism: an observational study

El‐Menyar¹,

Asim²,

Nabir³

et al. 2019

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: To evaluate the implications of elevated cardiac troponin (cTn) in patients presenting with pulmonary embolism (PE). Methods: We conducted a retrospective analysis for patients with PE between 2011 and 2015 with an average of 3 years follow-up. Patients were categorized into two groups based on the cTn status on admission (negative vs. positive) and RV/LV ratio (≤1.2 vs. >1.2). PE diagnosis was made by computed tomography pulmonary angiography (CTPA) examinations. Results: Among 220 patients with PE, 52.7% had positive cTn and 31.7% had RV dysfunction. Protein S and C deficiency were significantly higher in patients with negative cTn. Patients with positive cTn were more likely to have high-risk simplified pulmonary embolism severity index (sPESI), RV dilation, RV/LV ratio >1.2, severe inferior vena cava reflux and high Qanadli score (QS >18 points). Thrombolytic therapy was used in 15 patients; 9 (60%) of them had elevated troponin. Combined cTn and sPESI had higher sensitivity, negative predictive value and negative likelihood ratio to predict in-hospital mortality. Overall 30-day and 3 years morality were 10.0% and 22.3%; that were significantly higher in patients with positive troponin. Cox regression analysis showed that mortality increased 2.5 times with positive cTn after adjusting for age, sex, and RV dysfunction (adjusted HR 2.5; 95% CI: 1.25-5.01), P=0.009. Conclusions: Elevated cTn is independent predictor of short and long-term mortality. The predictive power of cTn increases when combined with the clinical probability score. Further, larger prospective studies are needed to confirm the findings of the present study.

show abstract

mentioning

confidence: 99%

Implications of elevated cardiac troponin in patients presenting with acute pulmonary embolism: an observational study

El‐Menyar¹,

Asim²,

Nabir³

et al. 2019

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

In vitro Assessment of the Biofield Treated Test Item on Cardiac Function Using Rat Cardiomyocytes Cell Line (H9c2) via Multiparametric Analysis

Trivedi¹,

Jana²

2019

JHC

View full text Add to dashboard Cite

Introduction Heart disorders are the major concern of population health worldwide. According to WHO estimates 2018, 17.9 million peoples were died due to cardiovascular disorders. Aim The aim of this study was to investigate the cardioprotective activity of Biofield Energy Treated test item, Dulbecco's Modified Eagle Medium (DMEM) using rat cardiomyocytes (H9c2). Methods The test item (DMEM) was divided into three parts, first part received one-time Biofield Energy Treatment by a renowned Biofield Energy Healer, Mahendra Kumar Trivedi and was labeled as the one-time Biofield Energy Treated (BT-I) DMEM, while second part received the two-times Biofield Energy Treatment and is denoted as BT-II DMEM. The third part did not receive any treatment and defined as the untreated DMEM group. Results Cell viability of the test samples by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay showed 89.03% and 98.49% in the BT-I and BT-II groups, respectively suggested a nontoxic and safe in nature of the tested test item. The BT-I group showed 16.01% restoration of cell viability. The level of lactate dehydrogenase (LDH) was significantly inhibited by 50.37% and 49.35% in the BT-I and BT-II groups, respectively compared to the untreated DMEM group. Moreover, percent protection of creatine kinase-myocardial band (CK-MB) by 49.48% and 59.79% in the BT-I and BT-II groups, respectively, compared to the untreated DMEM group. Reactive oxygen species (ROS) level in terms of mean fluorescence unit (FU) was reduced by 6.64% in the BT-I group than untreated DMEM. Besides, BT-I and BT-II groups significantly increased the level of % apoptotic cells by 63.16% and 97.37% (p≤0.05), respectively than untreated DMEM. Conclusion Allover, results envisaged that Biofield Treatment significantly improved different cardiac parameters. Thus, Biofield Energy Treatment (The Trivedi Effect®) could be utilized as a cardio-protectant against several cardiac disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, etc.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Value of cardiac biomarkers in patients with acute pulmonary embolism

Cited by 2 publications

References 20 publications

Implications of elevated cardiac troponin in patients presenting with acute pulmonary embolism: an observational study

Implications of elevated cardiac troponin in patients presenting with acute pulmonary embolism: an observational study

In vitro Assessment of the Biofield Treated Test Item on Cardiac Function Using Rat Cardiomyocytes Cell Line (H9c2) via Multiparametric Analysis

Contact Info

Product

Resources

About